Posted on

FDA Clears Next-Gen Assay to Detect HIV-1 Drug Resistance Mutations

Posted on

The US Food and Drug Administration (FDA) has approved the Sentosa SQ HIV genotyping assay (Vela Diagnostics USA Inc) that uses next generation sequencing technology to detect HIV-1 drug resistance mutations from a blood sample.

Recent data suggest that the percentage of people living with HIV around the world that have resistance to some HIV drugs has increased from 11% to 29% since 2001, Peter Marks, MD, PhD, director of the FDA’s Center for Biologics Evaluation and Research.

This new assay “can help health care providers better tailor drug treatment for patients who are beginning antiviral therapy and also for those who have developed resistance to HIV drugs by helping to identify mutations in the HIV-1 virus that can impact the effectiveness of certain drugs,” said Marks.

Sentosa SQ is the first HIV drug resistance assay that uses next generation sequencing technology that the FDA has authorized for use.

Results of performance studies show that the assay has > 95% sensitivity and specificity in detecting 342 HIV drug resistant mutations, the FDA said.

“As a public health agency, the FDA is keenly aware of the threat of drug resistant infections and we’re focused on facilitating the development of safe and effective new treatments to give patients more options to fight life-threatening infections,” FDA Principal Deputy Commissioner Amy Abernethy, MD, PhD.

“This diagnostic provides a new way to select effective treatment options. The FDA remains committed to helping to make available to Americans more innovative medical products that help us face the challenges of managing HIV Infection.

The FDA reviewed the Sentosa assay under the de novo premarket review pathway, a regulatory pathway for new types of devices considered low-to-moderate risk. The FDA will develop special controls in addition to general controls that will help ensure the safety and effectiveness for the assay.

-GDMeds, an India Pharmacy Service company
 [Disclaimer]The Site is operated by GDMeds and all rights thereto are owned and reserved by GDMeds. The contents and works on these pages compiled by GDMeds are subject to copyright law. Copying, processing, distribution and any kind of use outside the limits of copyright law require the written consent of GDMeds In case the content is not created by GDMeds the copyrights of third parties are being observed. However, if a user becomes aware of a copyright infringement, GDMeds asks the user for notification. Upon notification of such violations, GDMeds will remove the content immediately.
[免责声明]本网站由印度极得美运营。印度极得美拥有和保留一切权利。印度极得美的网页内容及文档受版权法保护。复制、加工、传播及任何超出版权法限制的任何使用行为均必须得到印度极得美书面许可。如相关内容如非由印度极得美创作,需遵守第三方的版权,特别是标示为第三方内容的。如用户发现侵犯版权的行为,请通知极得美。一旦收到违反通知,极得美将立刻移除相关内容。
[отказ]Сайт управляется GDMeds, и все права на него принадлежат и зарезервированы GDMeds. Содержание и работы на этих страницах, составленные GDMeds, защищены законом об авторском праве. Копирование, обработка, распространение и любое использование вне пределов авторского права требуют письменного согласия GDMeds. Если контент не создан GDMeds, то соблюдаются авторские права третьих лиц. Однако, если пользователь узнает о нарушении авторских прав, GDMeds запрашивает у пользователя уведомление. После уведомления о таких нарушениях GDMeds немедленно удалит контент